RecruitingPhase 2NCT06561347
Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WM
Studying Waldenström macroglobulinemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Massachusetts General Hospital
- Principal Investigator
- Andrew Branagan, MD, PhDMassachusetts General Hospital
- Intervention
- Zanubrutinib(drug)
- Enrollment
- 55 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2027
Study locations (5)
- Colorado Blood Cancer Institute (CBCI), Denver, Colorado, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
- Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
- Dana Farber Cancer Institute, Boston, Massachusetts, United States
- University of Texas Southwestern Medical Center, Dallas, Texas, United States
Collaborators
BeiGene
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06561347 on ClinicalTrials.govOther trials for Waldenström macroglobulinemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07387471Study to Assess Change in Disease Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed or Refractory (R/R) Waldenström Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)AbbVie
- RECRUITINGPHASE2NCT05099471Efficacy of Venetoclax in Combination With Rituximab in Waldenström's MacroglobulinemiaChristian Buske
- RECRUITINGPHASE2NCT05190705Loncastuximab Tesirine in WMShayna Sarosiek, MD
- RECRUITINGNCT05093153Spanish Registry of Patients With IgM Monoclonal GammopathiesFundación Española de Hematología y Hemoterapía
- ACTIVE NOT RECRUITINGPHASE2NCT04624906Bendamustine, Rituximab and Acalabrutinib in Waldenstrom's MacroglobulinemiaSunnybrook Health Sciences Centre
- ACTIVE NOT RECRUITINGPHASE2NCT04273139Ibrutinib + Venetoclax in Untreated WMDana-Farber Cancer Institute
- RECRUITINGPHASE2, PHASE3NCT04061512Rituximab and Ibrutinib (RI) Versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as Initial Therapy for Waldenström's MacroglobulinaemiaUniversity College, London
- ACTIVE NOT RECRUITINGPHASE1NCT01209871Vaccine Therapy in Treating Patients With Lymphoplasmacytic LymphomaM.D. Anderson Cancer Center